
GSK has announced that in 2024 it intends to start phase 3 trials of a low carbon version of its …

The FDA has released that GSK would be voluntarily recalling close to 600,000 of its Ventolin asthma inhalers across the …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

